Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

Protein 80

Protein Antibody Engineer Development 80

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Secondary, there is a growing interest in replacing the cytotoxic head with non-toxic alternatives, like protein degraders.

Antibody 82

Antibody FDA Approval Drugs Development 82

Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. The post Antibody therapy shows anti-tumour activity in advanced cancer appeared first on Drug Discovery World (DDW).

Antibody 116

Antibody Immune Response Trials Clinical Trials 116

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The post Ono Pharmaceutical enters research deal with Monash University appeared first on Pharmaceutical Technology.

Research 130

Research Antibody Sales Development 130

Pharma Mirror

OCTOBER 6, 2021

Limerick, Ireland: Irish SFI-funded research centre SSPC has announced a major collaboration with five of the world’s leading BioPharma companies that aims to reduce waste, maintain standards and minimise costs in pharmaceutical processes. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

Drug Discovery World

MAY 7, 2024

DDW Editor Reece Armstrong speaks to David Chau , Global Bioprocess Application Specialist, Separation and Purification Sciences Division, 3M, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes. RA: What are some of the current limitations for producing mAbs?

Antibody 59

Antibody Production Manufacturing Engineer 59

Bio Pharma Dive

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Protein 177

Protein Antibody Drugs Research 177

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 177

FDA Approval Drugs Protein Antibody 177

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours.

Development 130

Development Research Antibody Engineer 130

XTalks

SEPTEMBER 30, 2020

While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. Two recent studies have shown that individuals who lack an important immune factor may have reduced ability to fight the virus.

Antibody 135

Antibody Genetics Research In-Vitro 135

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

BioSpace

NOVEMBER 7, 2022

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech to develop therapeutic antibodies or small molecules that target membrane proteins.

Protein 75

Protein Licensing Licensing Antibody 75

Drug Discovery World

DECEMBER 20, 2022

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. BII is an international enterprise foundation with a non-profit objective of incubating and accelerating world-class life science research. Macromolecular structures.

Protein 52

Protein Life Science Antibody Business Development 52

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine. Their results are published in Circulation.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Scienmag

APRIL 22, 2021

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.

Antibody 46

Antibody Protein Scientist Research 46

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

Medical Xpress

FEBRUARY 3, 2023

A study led by researchers from Karolinska Institutet has now identified a drug candidate for the treatment of fatty liver. The preclinical study, published in the Journal of Hepatology, indicates that an antibody that blocks the protein VEGF-B presents a possible therapeutic option for fatty liver disease.

Antibody 75

Antibody Protein Drugs Research 75

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

JULY 6, 2023

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Semaphorin-3A is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton.

Antibody 52

Antibody Trials Genetics Protein 52

Roots Analysis

AUGUST 9, 2023

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. Around 50% of the articles focused on novel antibody therapies were published post-2020.

Antibody 52

Antibody Marketing Development Engineer 52

Drug Discovery World

APRIL 30, 2024

This eBook, sponsored by Thermo Fisher Scientific, explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future.

Drugs 52

Drugs Antibody Engineer Protein 52

Drug Discovery World

AUGUST 16, 2023

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Antibody 52

Antibody Immune Response Protein Research 52

Drug Discovery World

AUGUST 25, 2023

For comparison, Schulz said, three new anti-amyloid antibodies used to treat AD have shown they slow disease progression by 25%, 27%, and 35%. Enhancing the efficiency of immune cells “We hypothesise that the reduced risk of AD associated with vaccines is likely due to a combination of mechanisms,” another researcher Avram Bukhbinder said.

Antibody 52

Antibody Vaccination Vaccine Protein 52

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Research 52

Research Drugs Gene Therapy Genetics 52

Drug Discovery World

SEPTEMBER 1, 2022

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

Antibody 52

Antibody In-Vitro Development Recombinant Antibody 52

Drug Discovery World

APRIL 30, 2024

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. The post New ebook: Drug discovery and the impact of mAbs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Drugs Clinical Research Engineer 52

Drug Discovery World

APRIL 11, 2024

By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies. SG: Without a doubt the highlight of my career was the day that I learned that an antibody I had discovered and advanced into the clinic demonstrated a positive response in patients.

Research 59

Research Immune Response Antibody Medicine 59

Drug Discovery World

JULY 24, 2023

Talquetamab is a subcutaneous bispecific antibody that binds G protein-coupled receptor class C group 5 member D (GPRC5D), a novel target on multiple myeloma cells, and CD3, on T-cells. The post CHMP recommendation for bispecific antibody talquetamab appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Licensing Licensing Medicine 52

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135